Drug intelligence / Profile preview

225Ac-girentuximab

Development stage: Preclinical
Lead developer: Telix Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

225Ac-girentuximab is a monoclonal antibody targeted to carbonic anhydrase IX (CAIX), conjugated with actinium-225, a radioactive isotope, for the treatment of renal cancer. It employs ionizing radiation to target and destroy cancer cells, particularly those in hypoxic tumor environments, such as clear cell renal cell carcinoma (ccRCC). The drug is part of Telix Pharmaceuticals' portfolio and is being developed as a potential therapeutic agent in oncology, particularly for renal cancer.

Other names: 225Ac-DOTA-girentuximab

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on 225Ac-girentuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 225Ac-girentuximab.

Explore the full profile